TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06060925

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound imaging
Description: B-mode, color Doppler, shear wave elastography

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound imaging
Description: B-mode, color Doppler, shear wave elastography

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound imaging
Description: B-mode, color Doppler, shear wave elastography

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioimpedance spectroscopy
Description: Multifrequency bioimpedance spectroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioimpedance spectroscopy
Description: Multifrequency bioimpedance spectroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioimpedance spectroscopy
Description: Multifrequency bioimpedance spectroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: High density electromyography

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: High density electromyography

Intervention type: DIAGNOSTIC_TEST
Intervention: Electromyography
Description: High density electromyography

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical examination
Description: Comprehensive musculoskeletal physical examination, including range of motion, and quantitative sensory testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical examination
Description: Comprehensive musculoskeletal physical examination, including range of motion, and quantitative sensory testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical examination
Description: Comprehensive musculoskeletal physical examination, including range of motion, and quantitative sensory testing
Study: NCT06431594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5733584
Description: GSK5733584 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5733584
Description: GSK5733584 will be administered
Study: NCT06168552

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Injection of fluorescent developer (anti-EGFR-IR800CW)
Description: The patient underwent Da Vinci robot or fluorescent laparoscopy-assisted radical resection of pancreatic cancer, and anti-EGFR antibody-IR800CW imaging agent was injected in the day before surgery, and fluorescence detection was performed
Study: NCT05005429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa (M7824) is a bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β trap) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1).~Day 1 of week 1 of treatment will start within 1-5 days from enrollment. Cycles will be administered every 2 weeks (±3 days) until progression or other reason to discontinue. If a pseudoprogression is suspected patient is allowed to continue treatment until loss of clinical benefit as judged by principal investigator and after the permission from the trial chair is granted.~On Day 1 of each cycle (QW2), all eligible patients will receive:~Bintrafusp alfa (M7824): 1200mg, IV infusion over 60 minutes Current experience revealed that IRRs to bintrafusp alfa occur seldomly and are generally mild to moderate in severity. Therefore, administration of a premedication is generally not required.
Study: NCT05929274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 milliampere (mA) from the onset of stimulation and applied for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: For the sham condition (sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
Study: NCT05343182

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Technique
Description: This operation is performed using modified anesthesia care/deep sedation (MAC) for anesthesia. The vestibule is removed to the boundary of Harts line. The surgical flap for this procedure is the Hymen plus 1 cm of the vagina.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Technique
Description: This operation is performed using an Laryngeal Mask Airway (LAM), (modified anesthesia care/deep sedation) for anesthesia. The vestibule is removed 0.5 to 1 cm beyond the boundary of the Hart's line. The Hymen plus 1 cm of the vagina is excised.
Study: NCT05777187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: The intervention will consist of clinical decision support alerts in the electronic health record directed towards anesthesiologists caring for patients with preexisting cognitive impairment. This intervention will alert towards delirium risk informed by history of cognitive impairment and promote 12 evidence based best practices during care for perioperative patients.
Study: NCT05964218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food-Body-Mind Intervention
Description: The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
Study: NCT06650527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Empathy Training
Description: Participants will engage in a mentalization activity by captioning photos of their care recipients, reflecting on what the care recipient might be thinking or feeling. Over 10 days, caregivers will take 3-5 daily pictures of their care recipient and caption each with descriptive text representing the recipient's inner voice. This task encourages caregivers to consider the care recipient's perspective and motivations behind their behavior or emotional experiences. Photos will be shared securely via encrypted email. Utilizing accessible smartphone technology, the study allows caregivers to capture and reflect on meaningful moments with their care recipients
Study: NCT04524325

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trans men
Description: We are studying the effects of testosterone taken by trans men on mechanisms of blood pressure control and comparing those results to cisgender women that have normal (ie lower) testosterone levels.
Study: NCT04967534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WB-EMS
Description: Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied. After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 12 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping, and lower extremity strength will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by the rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)). WB-EMS will be fully supervised one-on-one.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: social contact control group
Description: Psycho-social intervention with participants randomized to the control group receiving (if wanted) the same social contact time (20-30 minutes/week) as the WB-EMS group. Depending on personal preferences and Covid-19 restrictions this will be done by phone or in-person one-on-one. Health-related topics and/or general chatting will be offered.
Study: NCT06115447

Intervention type: PROCEDURE
Intervention: lung suturing with polyglactin
Description: lung suturing with polyglactin

Intervention type: PROCEDURE
Intervention: ung suturing with polypropylene
Description: ung suturing with polypropylene
Study: NCT06650527

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Condition
Description: In the control condition, participants will be asked to take 3-5 daily photographs of nature over 10 days. They will be asked to caption each photo with a description of what they see. This exercise will involve many of the same activities as the cognitive empathy training, except that participants will not be mentalizing or taking the the perspective of their PLWD or anyone else.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre and post intervention blood spot collection
Description: At their initial study visit, participants will provide a blood spot sample for measurement of C-reactive protein, pro-inflammatory cytokines and Epstein-Barr virus antibody titers.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pre and post intervention blood spot collection
Description: At their initial study visit, participants will provide a blood spot sample for measurement of C-reactive protein, pro-inflammatory cytokines and Epstein-Barr virus antibody titers.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre and post intervention MRI session
Description: In this study, caregivers will be positioned in a Siemens Trio 3T MRI scanner for functional imaging. They will view images of their care recipient care recipient, other similar care recipients care recipient, and photographs of friends or family members, pressing a button each time they see their care recipient care recipient's photo to monitor attention. The task involves viewing eight photos of four individuals with happy and neutral expressions, followed by rest periods. This sequence repeats five times, with each stimulus presented for 5 seconds and inter-trial intervals of 2, 3, or 4 seconds, totaling 11 minutes and 15 seconds. A subsequent 10-minute diffusion-weighted scan will assess brain white matter integrity, using 60 diffusion directions. All scans will be completed within 40 minutes.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pre and post intervention MRI session
Description: In this study, caregivers will be positioned in a Siemens Trio 3T MRI scanner for functional imaging. They will view images of their care recipient care recipient, other similar care recipients care recipient, and photographs of friends or family members, pressing a button each time they see their care recipient care recipient's photo to monitor attention. The task involves viewing eight photos of four individuals with happy and neutral expressions, followed by rest periods. This sequence repeats five times, with each stimulus presented for 5 seconds and inter-trial intervals of 2, 3, or 4 seconds, totaling 11 minutes and 15 seconds. A subsequent 10-minute diffusion-weighted scan will assess brain white matter integrity, using 60 diffusion directions. All scans will be completed within 40 minutes.
Study: NCT05724329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + Dasatinib + Quercetin (neoadjuvant)
Description: Patients receive Tislelizumab (IV) on day 1, dasatinib (PO) on day 1,2,3 and quercetin (PO) on day 1,2,3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + Dasatinib + Quercetin (adjuvant)
Description: Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10
Study: NCT05208060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV130
Description: Treatment administered sublingually

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment administered sublingually
Study: NCT06601114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol Group
Description: Group A: Paracetamol Group will receive Oral form of paracetamol with dosage of 15mg/kg every 6 hours for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen group
Description: Group B: Ibuprofen Group will receive oral form of ibuprofen at initial dosage of 10mg/kg followed by 5mg/kg after 24 hours and 48 hours.
Study: NCT04838405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: Synthetic Peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: Synthetic Peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: Synthetic Peptide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05893485

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy Intervention
Description: Music Therapy Sessions. There will be 4 scheduled music therapy sessions, and a postpartum follow up.
Study: NCT05023551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-0390
Description: DSP-0390 administered orally
Study: NCT04793360

Intervention type: DEVICE
Intervention: LiverCare
Description: The LiverCare kits contains Streck tubes and PAX gene tubes, which will be collected at the surveillance schedule outlined above, but also prior to any liver biopsy or DSA measurement. For patients who have a histological diagnosis of allograft rejection who are undergoing treatment, serial monitoring of LiverCare will be performed following the schedule above. All research blood tests will be timed with standard clinical testing to avoid any additional needle sticks.
Study: NCT05424406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active phototherapy
Description: Timed bright light exposure delivered in a controlled laboratory setting (10,000 photopic lux) designed to delay the DLMO to 4 am or later.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control phototherapy
Description: Timed less intense light exposure delivered in a controlled laboratory setting (100 photopic lux) that still has a perceptible alerting effect but is not designed to shift circadian phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep education control
Description: Sleep duration recommendations will be equivalent to the CBT group (8 hours of sleep opportunity) to ensure that outcomes are not confounded by time in bed. Materials in the sleep education control condition will be separated into weekly electronic materials monitored for engagement and completion.
Study: NCT05557110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Reduced-intensity chemotherapy followed by Blinatumomab
Study: NCT06350643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Health Block Culturally Tailored training
Description: This online course will be developed for healthcare providers and will fill gaps in knowledge and attitudes toward lung cancer screening and smoking not covered by Health Disparities and Lung Cancer Screening (HDLCS) training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Health Block Culturally Tailored training
Description: This online course will be developed for healthcare providers and will fill gaps in knowledge and attitudes toward lung cancer screening and smoking not covered by Health Disparities and Lung Cancer Screening (HDLCS) training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Disparities and Lung Cancer Screening training
Description: The Health Disparities and Lung Cancer Screening training is an online course that covers disparities in lung cancer and smoking, patient barriers to lung cancer screening, and provider resources for addressing common barriers.
Study: NCT05048134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2300
Description: HRS2300 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2300、 SHR-1316
Description: HRS2300 combined with SHR-1316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2300、SHR-1701
Description: HRS2300 combined with SHR-1701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2300、trametinib
Description: HRS2300 combined with trametinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS2300、Almonertinib
Description: HRS2300 combined with Almonertinib
Study: NCT04730609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect
Study: NCT04300192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study: NCT06236802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProVee device
Description: ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
Study: NCT06653907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine Sodium (LT4) Tablets
Description: Participants in our study will determine the dosage of L-T4 based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in our study will determine the dosage of placebo based on their weight (BW):~1. BW ≥50kg: Starting with a daily dose of 1 tablet;~2. BW \< 50kg: Starting with a daily dose of half a tablet.~At 12 weeks, 18-20 weeks, 24-26 weeks, and 34-36 weeks of gestation, the serum TSH, FT3, and FT4 will be measured, and investigator will adjust dosage according to TSH:~1. When TSH \> ULRR, the participants will receive L-T4 in addition to their original medication, and additional unplanned follow-up;~2. When TSH at 2.5mIU/L-ULRR, add 1/4 tablet of medictaion;~3. When TSH at LLRR -2.5mIU/L, maintain the original dose;~4. When TSH \<LLRR, reduce 1/4 tablets of medictaion.~5. If TSH continues to be lower than LLRR after discontinuation, investigator will measure FT4, TRAb and other indicators to determine if it is clinical hyperthyroidism. If so, antithyroid drugs will administered according to guidelines. Participants will stop all trial medictaion after delivery.
Study: NCT05510583

Intervention type: OTHER
Intervention: Control group
Description: Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2013 and 30/06/2015. Patients received traditional paper-based blood glucose monitoring.

Intervention type: OTHER
Intervention: Treated group
Description: Retrospective study on pregnant women (≥18 years) with gestational diabetes who gave birth between 01/01/2021 and 31/12/2021. Patients received remote monitoring with myDiabby Healthcare
Study: NCT06654479

Intervention type: OTHER
Intervention: In the newborns in the study, changes in body temperatures during routine nursing interventions of the nurses of the clinic were examined.
Description: The study is an observational study. The newborns were not intervened by the researcher. Body temperature changes were observed during routine practices of nurses in the clinic.
Study: NCT06654973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMP-produced SARS-CoV-2 Delta strain
Description: The challenge virus used in Sing-CoV study is the same as that used in COVHIC002 study. It was originally obtained in mid 2021 from a nose-throat swab from an otherwise healthy young adult with mild COVID-19 in the community. The procedure for isolation, storage, preparation, and administration of challenge virus in this study (Sing-CoV and COVHIC002) is the same as used in the first SARS-CoV-2 human challenge study (COVHIC001) at Imperial College London and the same as used in the COV-CHIM01 (NCT04864548) SARS-CoV-2 human challenge study at University of Oxford.